Sunovion Pharmaceuticals Inc. today announced that results of a pivotal Phase 2/3 study evaluating novel drug candidate dasotraline in children ages 6 to 12 years with attention deficit hyperactivity disorder showed statistically significant improvement in the 4mg/day dose arm compared to placebo. The 2mg/day dose arm did not demonstrate a statistically significant difference from placebo.